Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03780517
Title Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Boston Pharmaceuticals
Age Groups: senior | adult
Covered Countries USA | FRA | ESP | BEL

Facility Status City State Zip Country Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Institut Jules Bordet Bruxelles Belgium Details
UZ Leuven Leuven Belgium Details
Institut Bergonié Bordeaux France Details
Centre Léon Bérard Lyon France Details
Hôpital Pitié-Salpêtrière Paris France Details
Institut Gustave Roussy Villejuif France Details
Prince of Wales Hospital Hong Kong Hong Kong Details
Chungbuk National University Hospital Cheongju-si Korea, Republic of Details
Seoul National University Bundang Hospital Gyeonggi-do Korea, Republic of Details
Asan Medical Center Seoul Korea, Republic of Details
Korea University Anam Hospital Seoul Korea, Republic of Details
Severance Hospital, Yonsei University College of Medicine Seoul Korea, Republic of Details
Hospital Universitario Virgen de la Victoria Málaga Andalucia 29010 Spain Details
Hospital Germans Trias i Pujol Badalona Spain Details
Instituto Oncológico Dr. Rosell, S.L. Barcelona Spain Details
Start Madrid - Ciocc Madrid Spain Details
START MADRID-FJD, Hospital Fundación Jiménez Díaz Madrid Spain Details
Taichung Veterans General Hospital Taichung Taiwan Details
National Taiwan University Hospital Taipei Taiwan Details
*Shaded cells indicate that there was no data available from for the field